BITLEVEX
BITLEVEX is a developing platform that provides a variety of financial services.
BITLEVEX
Industry:
Cryptocurrency Financial Exchanges Financial Services FinTech Information Technology
Founded:
2019-02-01
Address:
Tallinn, Harjumaa, Estonia
Country:
Estonia
Website Url:
http://www.bitlevex.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
50.27 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Apple Mobile Web Clips Icon PHP Google MailChannels Create React App
Similar Organizations
Algbra
Algbra is a developer of a financial services application to track carbon footprints and manage money.
CryptoIndexSeries
AI-powered Data, Trading and Portfolio Analytics Tools for Crypto Markets
DeTech Studios
DeTech Studios is a Defi platform.
Gate.io
Gate.io is a crypto exchange platform that provides trade, investment, and digital wallet services.
Heron Data
We categorise and label bank transaction data.
iSunOne
Better Banking on Blockchain, Leading Global Blockchain-based Financial Service Platform
Mono
Neobank for SMBs in Colombia
Ecex Exchange
Ecex Exchange is a trading and depository platform for digital assets.
Current Employees Featured
Founder
Investors List
GEM Digital Ltd.
GEM Digital Ltd. investment in Venture Round - BITLEVEX
Official Site Inspections
http://www.bitlevex.com Semrush global rank: 54.46 K Semrush visits lastest month: 2.19 M
- Host name: 104.21.43.72
- IP address: 104.21.43.72
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "BITLEVEX"
Enhanced CAR-T Cell Characterization with a Moxi GO II
Once the CAR-T cells have been activated for reintroduction to the patient, final counting and viability QC checks are critical. Moxi GO II provides a simultaneous count of thousands of cells โฆSee details»
Streamlined measurement of chimeric antigen receptor T-cell ...
The successful development of CD19-targeted chimeric antigen receptor (CAR) T-cell therapies has led to an exponential increase in the number of patients recieving treatment and the โฆSee details»
Comparison of two lab-scale protocols for enhanced mRNA-based CAR-T โฆ
Process development for transferring lab-scale research workflows to automated manufacturing procedures is critical for chimeric antigen receptor (CAR)-T cell therapies. Therefore, the key โฆSee details»
Sensitivity and Specificity of CD19.CAR-T Cell Detection by Flow ...
Chimeric-antigen-receptor-T (CAR-T) cells are currently revolutionizing the field of cancer immunotherapy. Therefore, there is an urgent need for CAR-T cell monitoring by clinicians to โฆSee details»
National Center for Biotechnology Information
We would like to show you a description here but the site wonโt allow us.See details»
Immunophenotyping | CAR T cell transduction | Protocol | Miltenyi ...
This application protocol describes the analysis of the surface expression of chimeric antigen receptors (CARs) on T cells after transduction. To demonstrate the state-of-the-art panel, CAR โฆSee details»
CAR T cell viability release testing and clinical outcomes: is ... - PubMed
Nov 21, 2019 CAR T cell viability release testing and clinical outcomes: is there a lower limit?See details»
National Center for Biotechnology Information
We would like to show you a description here but the site wonโt allow us.See details»
CAR-T Therapy Research & Development | Sartorius
Chimeric antigen receptor (CAR) T-cell therapy represents a major advancement in the fight against cancer and a paradigm shift toward personalized medicine. Although treatment with โฆSee details»
Review: Sustainable Clinical Development of CAR-T Cells โ โฆ
Abstract T cells modified for expression of Chimeric Antigen Receptors (CARs) were the first gene-modified cell products approved for use in cancer immunotherapy. CAR-T cells โฆSee details»
Improving CAR T cell therapy by optimizing critical quality attributes
Apr 1, 2020 Manufacturing CAR-T cells commonly occurs over 7 to 12 days and begins with an apheresis collection, followed by target cell selection and enrichment, CAR gene transfer, and โฆSee details»
The Post-Thaw Recovery of Cryopreserved Chimeric Antigen Receptor (CAR ...
Dec 7, 2017 The post thaw viability of CAR T-cells cryopreserved post culture was greater than cryopreserved peripheral blood CD3+ cells. Cryopreservation at either end of CAR T-cell โฆSee details»
Choice of activation protocol impacts the yield and quality of CAR T ...
Nov 29, 2024 Older samples generated fewer, more differentiated CAR T cells than young samples, and the ฮฑCD3/CD28 mAb protocol exacerbated this, further reducing yield and โฆSee details»
Decentralized manufacturing of anti CD19 CAR-T cells using
Nov 8, 2022 Validation run data, as part of a pre-clinical trial safety evaluation, demonstrates the successful and robust manufacturing of anti-CD19 CAR-T cells with T cell expansion of 25 to โฆSee details»
Home - Beckman Coulter Vi-Cell Reagents
Vi-Cell XR Reagent Packs Cell Viability Incorporated manufactures Beckman Coulter Vi-Cell Reagents for the Vi-CELL automated cell viability analyzer. Reagents are packaged in โฆSee details»
CAR T Cell Registration in SFDA - PharmaKnowl
Jul 9, 2025 Learn about the CAR T Cell registration in Saudi Arabia, what are the SFDA submission requirements on clinical and quality CMC files.See details»
Improving CAR T Cell Therapy by Optimizing Critical Quality โฆ
Whether as a cure or bridge to transplant, chimeric antigen receptor (CAR)-T cell therapies have shown dramatic outcomes for the treatment of hematologic malignancies, and particularly โฆSee details»
Best practices for the development, analytical validation and clinical ...
Dec 29, 2020 2.2 Panel design Panel design for CAR T cells will follow the current best practices for the design of flow cytometric methods with regard to antigen fluorophore pairing, reagent โฆSee details»
Accelerate your CAR-T cell workflow - BD Biosciences
Accelerate your CAR-T cell workflow From the early steps in exploratory studies to the manufacturing QC process and clinical trials of CAR-T cells, BD Biosciences offers a โฆSee details»
Quality Control and Nonclinical Research on CAR-T Cell โฆ
Feb 1, 2019 Adoptive cell therapy using chimeric antigen receptor T (CAR-T) cells, which is a promising cancer immunotherapy strategy, has been developing very rapidly in recent years. โฆSee details»